|
Poor Lungs
And Heart Attacks Related To Leptin Levels
It is known
from the medical literature that poor lung function can often lead
to heart attacks making it one of the important causes of premature
death for patients with poor lungs (due to emphysema, chronic bronchitis,
COPD etc.).
A research team
led by Dr. Don Sin from the University of Alberta, Edmonton, Canada,
asked the question recently whether there may be a circulating factor
that would be responsible for this association of poor lung function
and increased cardiovascular disease.
They studied
serum leptin and a variety of other inflammatory markers such as
C reactive protein, leukocytes, and fibrinogen in 2808 participants
in the Third National Health, Nutrition, and Examination Survey.
Apart from blood tests they also measured lung function by spirometry
(forced expiratory volume in 1 second, called FEV1). The leptin
levels found in these patients were then divided into 5 groups from
low to high levels. They also carefully adjusted the data for body
mass index, sex, age and other factors. They compared the group
with the lowest leptin concentration (lowest quintile) with the
highest group of leptin concentration (highest quintile) and looked
for any significant differences in any of the markers.
Results:
The highest quintile group (high leptin in blood samples)
had also the highest other inflammatory markers in their blood (C-reactive
protein, leukocytes and fibrinogen). This group was the one that
was associated with advanced lung diseases as well as heart disease.
The authors of this study, which was recently published in a medical
journal (Thorax 2003;58:695-698), concluded that leptin plays an
important role, if not the major role, in the development of both
chronic lung disease and cardiovascular complications.
Links to lung
disease: http://www.nethealthbook.com/lungdisease.html
Links to heart
attacks:
http://www.nethealthbook.com/cardiovasculardisease_heartdisease.html
| §§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§ |
SARS
Due To SARS-Associated Coronavirus (SARS-CoV)
A comprehensive
paper was recently published online July 22, 2003 (Lancet 2003;
362: 263-70) regarding the causative microorganism of SARS.
Several investigators
have collaborated in this study from viral laboratories of Rotterdam/The
Netherlands, Hong Kong Special Administrative Region/China , Singapore,
London/UK, Hamburg/Germany, Paris/France and Geneva/Switzerland.
This study involved
isolation of the SARS-associated
coronavirus (SARS-CoV) from SARS patients who died from the disease,
propagation of the virus in an experimental animal model (cynomolgus
macaques) and causing SARS again with an injection of the isolated
virus back into a healthy experimental animal.
This, according
to the authors (Dr. Thijs Kuiken et al.), fulfils the Koch's postulates,
which is one of the fundamental laws in microbiology that has to
be fulfilled in order to claim a new infective organism. Dr. Robert
Koch was a German physician who had detected the causative organisms
of anthrax, tuberculosis and cholera and won the Nobel price for
physiology and medicine in 1905. He developed the four original
Koch's postulates that were subsequently modified to a total of
six. Here is a run down of the postulates and how it relates to
SARS:
1.
The specific organism should be present in all cases of animals
suffering from a specific disease, but should not be found in healthy
animals.
For SARS
this was fulfilled as this study, which was based on a thorough
analysis of 436 patients in six countries, showed. 75% of the suspected
cases were found in postmortem studies to contain the SARS-associated
coronavirus (SARS-CoV). In some patients other infectious agents
could also be isolated, but the primary causative agent was SARS-CoV.
2.
The specific organism should be isolated from a diseased animal
and grown in pure culture on artificial laboratory media.
Using an
experimental animal model, the virus was able to be isolated from
a diseased person and injected into a healthy animal that turned
sick with SARS. From this animal the virus could be isolated again
from cells of the infected airways and grown in tissue culture.
3. This
freshly isolated microorganism, when inoculated into a healthy laboratory
animal, should cause the same disease as in the original animal.
As already
explained under point 2 above, this has been shown with SARS.
4. The
microorganism should be able to be isolated again in pure culture
from the experimental infection.
This was
proven in this paper regarding SARS. It was even done with genetic
markers that were still present after passage from postmortem human
tissue into an experimental animal and from the final respiratory
tissue isolate of this newly infected animal.
5.
The infective agent can be filtered and the
filtrate contains the infective agent.
This
was proven for SARS and the exact classification of the virus was
possible because of the advanced genetic knowledge that is now available.
6. When
the virus enters the body or the experimental animal, there are
signs of the immune system attempting to rid the body of the infectious
organism.
Sophisticated
immune tests were performed that showed in more than one way that
the immune system attempted to rid the body of SARS, but was eventually
overwhelmed in the cases that did not survive.
Summary:
This
paper has conclusively proven that SARS is caused by a new type
of coronavirus, SARS-associated
coronavirus (SARS-CoV). In about 12% of cases there was another
virus type present, such as human metapneumovirus. This occasionally
was also present in lethal SARS cases as a secondary virus. Some
other flu-type viruses were also found in the non-SARS cases. However,
this paper has shown that SARS-associated
coronavirus (SARS-CoV) is what
causes SARS.
Link to SARS
chapter of Dr. Schilling's Net Health Book:
http://www.nethealthbook.com/infectiousdisease_respiratoryinfection.html
| §§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§ |
Asthma
And Wheezing Influenced By Family Lifestyle (Swedish Study)
A new study
from Sweden was published by Dr. Magnus Wickman and colleagues,from
the Karolinska Hospital in Stockholm, in the medical journal Allergy
2003;58:730-731,742-747. The authors of this study were analyzing
data of a prospective birth cohort study of 4089 children who were
born in Sweden between 1994 and 1996.
The families
were given health questionaires at the age of 2 months to assess
whether the family was adhering to the allergy prevention guidelines
(see below). Questionaires were again given at the age of 1 year
and 2 years of these children. Specific questions were asked regarding
environmental conditions in the house where the children lived.
In the mid 1990's allergy prevention guidelines were strongly recommended
to the public in Sweden regarding the value of breast feeding, the
avoidance of smoking inside the house in the presence of children,
also that a house should be kept well ventilated and without dampness.
All of these factors, as was stressed by the allergists in Sweden
who organized the campaign, would protect the immune system from
allergies against molds, dust mites as well as cigarette smoke and
should reduce the rates of asthma.
Here are the results in tabular form.
| Swedish
family lifestyle study |
| Agreement
with allergy guidelines: |
%
of asthma and wheezing at ages 1 and 2 of child: |
| 1
year |
2
years |
| Yes
(all three measures followed) |
6.8% |
12.6% |
| No
(one or none of measures followed) |
17.9% |
24.1% |
As can be seen
from this table, which is based on families without allergic
parents, a two-fold drop of asthma and wheezing occured when
the allergy prevention guidelines were followed in the house. With
allergic parents the children had an even greater benefit
as the reduction of asthma and wheezing was three-fold when compared
to controls who did not follow the guidelines. This is one of the
few studies, which shows conclusively that allergy prevention works!
Link to asthma
chapter of Dr. Schilling's Net Health Book:
http://www.nethealthbook.com/lungdisease.html
| §§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§ |
Stillbirth
Associated With High Coffee Consumption In Pregnancy
A study entitled
"Maternal consumption of coffee during pregnancy and stillbirth
and infant death in first year of life" by Dr. K. Wisborg et
al. was published recently in the British Medical Journal (BMJ 2003;
326: 420-423).
The pregnancy
outcome of 18,478 women who completed a questionnaire at their first
prenatal visit was studied. They were asked about coffee consumption
and the following 4 groups were identified: group 1 consisted of
the 43% of women who drank no coffee. Group 2 (34%) drank 1-3 cups
per day, group 3 drank 4-7 cups per day (18%). Group 4 drank 8 or
more cups per day (5%).
Here are the
results in tabular form.
| Stillbirth
coffee study |
| Groups
with varying amounts of coffee consumption: |
Risk
increase of stillbirth compared to group 1 as a control group |
| group
2 (1-3 cups per day) |
-
30% |
| group
3 (4-7 cups per day) |
80% |
| group
4 (8 or more cups per day) |
300% |
The surprising
result was that a small amount of coffee (1-3 cups per day) was
actually reducing the risk of stillbirth by 30% when compared to
women who drank no coffee at all. However, from 4 cups of coffee
per day or more there was a sharp increase of stillbirths within
the first year (=sum of stillbirths and deaths within the first
year of life).
The authors
suggest that physicians should advise their pregnant patients to
limit coffee consumption in pregnancy to 1 or 2 cups of coffee or
the equivalent of caffeinated drinks per day as a precautionary
measure.
| §§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§ |
West
Nile Virus (WNV) Vaccine Being Tested In Humans
According to
Dr. Tom Monath, the scientific officer of the Acambis
pharmaceutical company, human trials on a new vaccine for West
Nile virus (WNV) can begin as soon as the FDA will give the green
light (likely in October of 2003).
At the 2003
World Vaccine Conference in Montreal/Canada this summer Dr. Monath
explained that Acambis has been doing research for a new vaccine
against WNV since 1999 when this virus arrived in New York. The
virus belongs into the same group of flaviviruses as dengue fever,
yellow fever and Japanese encephalitis.
Yellow fever
has been successfully prevented by vaccination
with a live vaccine that has been modified considerably
(called 17D attenuated vaccine). This strain is basically a harmless
virus, which will induce a strong immune response in 100% of vaccinated
people. If this is repeated every 10 years, a vaccinated person
would be safe to travel in yellow fever infested areas. Based on
this knowledge the researchers of Acambis have created a chimera
virus where the yellow fever vaccine ( attenuated
virus 17D) is used as a vehicle in the center while the surface
has been modified by incorporating parts of the WNV into its envelope.
As this new vaccine virus has qualities of both the yellow fever
vaccine virus and the WNV, it is called a chimera virus. The same
technology has already been successfully applied to two other flavivirus
vaccines, namely the dengue fever vaccine and the Japanese encephalitis
vaccine.
The new WNV
vaccine has been tested extensively in mice and monkeys and has
been found sofar to be very safe and it is mounting a very good
immune response. It is timely that human trials are being done now
starting this fall as WNV seems to be expanding rapidly throughout
the United States and Canada. The vaccine would be needed particularly
for older people as in them the WNV disease presents much more violently
with a higher death rate. However, visitors from Europe to the US
and Canada will likely want to protect themselves as well before
they travel.
| §§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§§ |
|